ApiJect Systems announced that Raymond J. Guidotti joined the company as its new chief operating officer.
Stamford, Conn.-based ApiJect, which develops technologies for vaccines and injectable medicines to be filled, finished and delivered, made the personnel move effective on March 1, 2021, according to a news release.
Guidotti is a veteran of more than 30 years in the pharma space, working in global business, operational strategy and execution, supply chain management, manufacturing network design and capital project planning and execution.
He most recently served as group VP of global engineering, capacity planning and technical/operations services for the pharma services group within Thermo Fisher Scientific. He has also held executive leadership roles with Patheon Pharmaceuticals.
As ApiJect’s COO, Guidotti is set to work with CEO Franco Negron to work on the company’s growth strategy while also holding responsibility for ApiJect’s construction of a campus in Durham, N.C., that will be capable of producing up to 3 billion doses of injectable medicines annually. The campus is being paid for with a $590 million loan from the U.S. International Development Finance Corporation in addition to more than $200 million of privately raised capital.
In welcoming Mr. Guidotti to the ApiJect team, Mr. Negron, commented: “Ray Guidotti is the right person at the right time for ApiJect,” Negron said in the release. “He is a proven senior executive who will help drive our company’s rapid emergence as a technology innovator and leader in the development and production of safe, effective, efficient, high volume injection devices. His deep technical and operational experience means he understands and has executed the technical and strategic aspects of successful pharmaceutical operations. His engineering expertise coupled with his executive leadership in the pharmaceutical industry is exactly what ApiJect needs in our COO.
Negron and Guidotti have a history of professional collaboration dating back almost 20 years, Negron added, including the roles at Patheon and Thermo Fisher.
“As an engineer and pharmaceutical executive, I can say that I am thrilled to be joining ApiJect,” Guidotti said. “Blow-Fill-Seal technology is safe, cost-effective and holds tremendous promise for rapidly transforming the speed and scale at which vaccines and other therapeutic medicines can be delivered. ApiJect is at the forefront of this work. I’ve been fortunate in my career to work with some of the most incredible leaders in Pharma and to be a part of teams that have achieved many firsts and improvements in the industry.
“With ApiJect, I have a chance again to work with a world class leadership team and to continue building out our organization with the kind of talent that will lead the way in expanding access, reducing cost, and revolutionizing the way vaccines and medicines are distributed to communities throughout the world. I couldn’t be more excited to take on this challenge.”